Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Merizyme is a multi-ingredient digestive aid developed and marketed by Mercury Laboratories Ltd. It is formulated to treat various digestive disorders, including indigestion, bloating, flatulence, and gastric distress. The product is available in several forms: tablets, liquid/syrup, and pediatric drops. The tablet formulation combines digestive enzymes (fungal diastase and papain) with niacinamide (Vitamin B3), activated dimethicone (an anti-foaming agent), and activated charcoal (an adsorbent). The liquid formulation primarily utilizes fungal diastase and pepsin to assist in the breakdown of carbohydrates and proteins, while the infant drops include alpha-amylase and papain alongside carminative oils like anise, caraway, and dill oil. Merizyme is approved and marketed in India as an over-the-counter (OTC) pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Merizyme.